BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Scheduled to Post Earnings on Wednesday
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is scheduled to post its quarterly earnings results after the market closes on Wednesday, August 2nd. Analysts expect BioMarin Pharmaceutical to post earnings of ($0.21) per share for the quarter.
BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings data on Thursday, May 4th. The biotechnology company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.33. The company had revenue of $303.70 million during the quarter, compared to analysts’ expectations of $292.58 million. BioMarin Pharmaceutical had a negative return on equity of 22.71% and a negative net margin of 48.43%. BioMarin Pharmaceutical’s revenue for the quarter was up 28.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.53) earnings per share. On average, analysts expect BioMarin Pharmaceutical to post $-0.83 EPS for the current fiscal year and $-0.36 EPS for the next fiscal year.
Shares of BioMarin Pharmaceutical Inc. (NASDAQ BMRN) opened at 88.63 on Wednesday. The company’s 50-day moving average price is $90.74 and its 200-day moving average price is $90.01. BioMarin Pharmaceutical Inc. has a 52-week low of $78.42 and a 52-week high of $102.49. The stock’s market cap is $15.47 billion.
In related news, CEO Jean Jacques Bienaime sold 5,000 shares of BioMarin Pharmaceutical stock in a transaction dated Thursday, April 27th. The stock was sold at an average price of $95.72, for a total value of $478,600.00. Following the completion of the transaction, the chief executive officer now owns 243,194 shares in the company, valued at approximately $23,278,529.68. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Brian Mueller sold 7,482 shares of BioMarin Pharmaceutical stock in a transaction dated Monday, May 8th. The shares were sold at an average price of $91.87, for a total value of $687,371.34. Following the completion of the transaction, the senior vice president now owns 18,350 shares of the company’s stock, valued at approximately $1,685,814.50. The disclosure for this sale can be found here. In the last three months, insiders sold 87,024 shares of company stock valued at $8,066,526. Insiders own 2.50% of the company’s stock.
BMRN has been the subject of a number of research reports. Zacks Investment Research raised BioMarin Pharmaceutical from a “hold” rating to a “buy” rating and set a $107.00 price target for the company in a research report on Monday, May 1st. UBS AG initiated coverage on BioMarin Pharmaceutical in a research report on Wednesday, March 29th. They set a “neutral” rating and a $92.00 price target for the company. Vetr cut BioMarin Pharmaceutical from a “strong-buy” rating to a “buy” rating and set a $95.10 price target for the company. in a research report on Monday, April 10th. Credit Suisse Group reaffirmed a “buy” rating and set a $116.00 price target on shares of BioMarin Pharmaceutical in a research report on Friday, April 28th. Finally, Cowen and Company reaffirmed an “outperform” rating and set a $150.00 price target on shares of BioMarin Pharmaceutical in a research report on Tuesday, April 18th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and fourteen have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $111.05.
ILLEGAL ACTIVITY WARNING: This report was first reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/07/26/biomarin-pharmaceutical-inc-nasdaqbmrn-scheduled-to-post-earnings-on-wednesday.html.
About BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).
Receive News & Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.